Latest Breaking News On - Iotechnology alcls fr0010425595 - Page 1 : comparemela.com

BALLI-01 abstract demonstrates safety and preliminary efficacy of UCART22 in heavily pretreated r/r B-ALL populationNEW YORK, May 11, 2023 Cellectis , a clinical-stage biotechnology company. | May 11, 2023

North carolinaUnited statesNew yorkFrance generalMark frattiniAshleyr robinsonNicolas boisselPascalyne wilsonArthur strilCellectis the company euronext growthSecurities exchange commissionEuropean hematology associationEuronext growthHybrid congressChief medical officerUpdated results